about
1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosisBlood Cell Palmitoleate-Palmitate Ratio Is an Independent Prognostic Factor for Amyotrophic Lateral SclerosisReduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis[Environmental factors in ALS].Sex-dependent effects of chromogranin B P413L allelic variant as disease modifier in amyotrophic lateral sclerosisInhibition of β-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis.A clustering of conjugal amyotrophic lateral sclerosis in southeastern France.Elevated serum ferritin is associated with reduced survival in amyotrophic lateral sclerosis.Molecular imaging of microglial activation in amyotrophic lateral sclerosis.The importance of the SMN genes in the genetics of sporadic ALS.The evolution of infrahissian conduction time in myotonic dystrophy patients: clinical implicationsHomozygous SMN2 deletion is a protective factor in the Swedish ALS population.Value of nerve biopsy in patients with latent malignant hemopathy and peripheral neuropathy: a case series.Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.Functional Outcome of Hemorrhagic Transformation after Thrombolysis for Ischemic Stroke: A Prospective StudyManagement of amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis: a hormonal condition?Protein SUMOylation, an emerging pathway in amyotrophic lateral sclerosis.New therapy options for amyotrophic lateral sclerosis.Is there a paraneoplastic ALS?Current view and perspectives in amyotrophic lateral sclerosis.Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies.A novel p.E121G SOD1 mutation in slowly progressive form of amyotrophic lateral sclerosis induces cytoplasmic aggregates in cultured motor neurons and reduces cell viability.Management and therapeutic perspectives in amyotrophic lateral sclerosis.Untargeted 1H-NMR metabolomics in CSF: toward a diagnostic biomarker for motor neuron disease.Adjunctive perampanel in refractory epilepsy: Experience at tertiary epilepsy care center in Tours.Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis.Impaired glucose tolerance in patients with amyotrophic lateral sclerosis.Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices.Development of monoclonal antibodies to human kallikrein-related peptidase 6 (KLK6) and their use in an immunofluorometric assay for free KLK6.Causes of death in a post-mortem series of ALS patients.Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation.Benign lower limb amyotrophy due to TARDBP mutation or post-polio syndrome?Defining survival as an outcome measure in amyotrophic lateral sclerosis.Sleep disturbances in variant of Creutzfeldt-Jakob disease.A rare motor neuron deleterious missense mutation in the DPYSL3 (CRMP4) gene is associated with ALS.Peripheral myelin protein 22 gene duplication with atypical presentations: a new example of the wide spectrum of Charcot-Marie-Tooth 1A disease.Nerve Biopsy Is Still Useful in Some Inherited Neuropathies.July 2017 ENCALS statement on edaravone.Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment.
P50
Q28475721-21EF1E31-FB50-4876-8E6F-E9A3B2DD747FQ28546154-6358E4AE-A2BC-466F-8C6B-70EE40A6E969Q28943310-EA93BACC-32FC-4F38-842F-B7DB077C3929Q30361044-02E3B4EF-5236-48E7-8E9B-0C589489E9E2Q33640597-023E537B-C850-48D1-9BA0-255102F093E3Q33899405-F666A73B-05B1-4F00-95ED-E54050A18C21Q34191966-AECF7B2E-8B1F-438B-9F83-4E2443F1D531Q34425189-E285EBE8-15F5-47CA-A831-83BECAF1CA5BQ34541448-3CE8B683-73B2-4ED1-90B5-E6389531805DQ35013439-5CD92F9E-ED6A-4EA2-A0B4-44F0C68C7AF4Q35685801-646EB861-E214-45C4-B5D7-1DFB4479868AQ35899380-2309F9E4-C833-4B56-A6D8-48A17F3C8C96Q36151870-21DE701B-42A3-47F3-9E45-53F90B9F126AQ36202825-F66506BB-240D-4BFD-9D05-8E5D1F5BAED5Q36325806-6AF5DB2D-4624-4904-88ED-7B9AD8ECEE1CQ37165524-3CF5655C-4E49-406B-A435-DF9DE6F1816AQ38032904-C36BF70C-4EA0-4A61-8FA2-1D735DEE370DQ38071685-FFEA187A-D206-465C-9DA7-7DF163014694Q38121637-FFFDF4E8-2C35-4270-80DA-6C53726F70D8Q38256994-FC36904A-663A-4503-82FB-07BD2DA3693BQ38731625-A9F4E2EF-7B3E-4E3A-8665-C0569E411B6EQ38856824-614A48E2-2C95-452A-B735-B592372C7D36Q38946004-4AE7FF4E-CC63-45C9-97EE-445A101003F4Q38958585-F890983F-E889-483E-BFED-497CA1EED483Q39241061-CB097558-556A-480F-BA47-BE02A263F74DQ39619409-06B4F3B5-3298-443A-AD74-922086EC94BCQ41392222-9FC60C94-CF7B-420A-8759-79521D52A551Q43149662-C6072EB3-FC75-4C77-BA3A-12C0EC82865FQ43957482-370F21C4-BEA8-4188-B3E8-47959AB209E3Q44208129-A52F661A-5570-49AB-895E-6FB5AE3E5E22Q44211932-5D9C85F8-4E02-4E06-B5CC-DBA30325378FQ45245938-9D0D2B55-D64F-41C1-93AA-5CCB4F576A96Q45789345-A45811E1-9CAE-42C9-B1CE-84D259B3E3F7Q45977771-8AF6AC99-6879-4DA7-8FC5-65E5FF10B011Q46183223-EB56BED1-27B9-4FF7-AEC9-D2EB4A6B56A9Q46657841-B7BF0D83-84CB-4B87-8DAA-B104640AE557Q46732730-426D7966-B533-4850-B124-C323D95CFF7BQ47209663-EE0F0B5C-3CED-4702-8E7D-FD9D3813370FQ47606847-F2450A2E-8968-4FD9-A37B-0869996361C5Q47815494-0343236E-52D2-4BBA-82B0-96C05972C617
P50
name
Philippe Corcia
@en
Philippe Corcia
@nl
type
label
Philippe Corcia
@en
Philippe Corcia
@nl
prefLabel
Philippe Corcia
@en
Philippe Corcia
@nl